Legal, clinical, and ethical issues in bioequivalence research
Медицинская этика · 26.02.2026 · (1)
DOI: 10.24075/medet.2026.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Медицинская этика, online erschienen am 26.02.2026. Verfasst von SA Speshilova und 2 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Real-life clinical practice requires to confirm bioequivalence of medicinal products in everyday settings resulting in adequately assessed effectiveness and tolerability of drugs in diverse patient groups. When the studies are lacking, it cannot be warranted that therapeutic effects or safety profiles of the reproduced drug will be identical to those of original brand medicines, which may decrease the trust of doctors and patients in generics and, as a consequence, limit treatment affordability. Assessment of bioequivalence (or pharmacokinetic equivalence) of medicinal products (drugs) is currently considered one of the main types of biomedical quality control of reproduced (generic) medicines. The Russian pharmaceutical market is heavily dominated by generic drugs, which significantly outnumber original products. Thus, bioequivalence studies are of a huge economic and clinical value.
Zitieren
APA
Speshilova, S., Lileeva, E., & Lileeva, O. (2026). Legal, clinical, and ethical issues in bioequivalence research. Медицинская этика. https://doi.org/10.24075/medet.2026.003
Vancouver
Speshilova S, Lileeva E, Lileeva O. Legal, clinical, and ethical issues in bioequivalence research. Медицинская этика. 2026. doi:10.24075/medet.2026.003
BibTeX
@article{Speshilova2026,
author = {Speshilova, SA and Lileeva, EG and Lileeva, OA},
title = {Legal, clinical, and ethical issues in bioequivalence research},
journal = {Медицинская этика},
year = {2026},
number = {1},
doi = {10.24075/medet.2026.003}
}
EUVIMED